Mereo BioPharma Group PLC (MREO)
3.26
+0.15
(+4.82%)
USD |
NASDAQ |
May 03, 16:00
3.265
0.00 (0.00%)
After-Hours: 20:00
Mereo BioPharma Group Cash from Operations (TTM): -21.13M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -21.13M |
| June 30, 2023 | -42.74M |
| December 31, 2022 | -48.82M |
| June 30, 2022 | -43.58M |
| December 31, 2021 | -7.071M |
| June 30, 2021 | -11.19M |
| December 31, 2020 | -38.62M |
| June 30, 2020 | -38.94M |
| Date | Value |
|---|---|
| December 31, 2019 | -60.22M |
| June 30, 2019 | -44.73M |
| December 31, 2018 | -29.36M |
| June 30, 2018 | -49.45M |
| December 31, 2017 | -43.45M |
| June 30, 2017 | -36.17M |
| December 31, 2016 | -36.60M |
| June 30, 2016 | -14.07M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-60.22M
Minimum
Dec 2019
-7.071M
Maximum
Dec 2021
-35.70M
Average
-40.84M
Median
Cash from Operations (TTM) Benchmarks
| Biodexa Pharmaceuticals Plc | -8.515M |
| NuCana PLC | -32.90M |
| TC BioPharm (Holdings) PLC | -13.16M |
| Adaptimmune Therapeutics PLC | -140.88M |
| Autolus Therapeutics PLC | -145.59M |